Skip to main navigation
Kyverna Therapeutics Logo
  • Overview
  • News Releases
  • Events & Presentations
  • Governance
    • Governance Overview
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Financials
    • SEC Filings
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Investor Relations

Minimum 15 minutes delayed. Source: LSEG

Our Mission

Our Mission

Liberating autoimmune patients through the curative potential of cell therapy.

Read More
Corporate Presentation

Corporate Presentation

JPMorgan Investor Presentation – January 2025

News Releases

Press Releases

January 13, 2025
Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
December 13, 2024
Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
November 14, 2024
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
View All News

Investor Contact

drafts InvestorRelations@kyvernatx.com
drafts Media@kyvernatx.com
phone_iphone +1 510.925.2492
© 2025 Kyverna Therapeutics

Social Media

  • LinkedIn opens in new window
  • Glassdoor opens in new window
Search Investors